THURSTON, SPRINGER, MILLER, HERD & TITAK, INC.
Position in MRK — Merck & Co., Inc.
CIK 319933
INDIANAPOLIS, IN
Position in MRK
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$469,782
+$173,649 QoQ
Shares Held
3,656
+48.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.26%
of 13F equity value
Holder Rank
#2,748
of 3,769 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MRK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026THURSTON, SPRINGER, MILLER, HERD & TITAK, INC. holds $12,028,760 across 13 Drug Manufacturers - General names. MRK ranks #5 (3.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
4,965 | $5,955,106 | |
| 2 | JNJ |
Johnson & Johnson
|
8,301 | $2,108,119 | |
| 3 | ABBV |
AbbVie Inc.
|
7,148 | $1,798,661 | |
| 4 | AMGN |
Amgen Inc
|
3,012 | $1,090,653 | |
| 5 | MRK |
Merck & Co., Inc.
This page
|
3,656 | $469,782 | |
| 6 | AZN |
Astrazeneca PLC
|
896 | $169,894 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
2,607 | $150,200 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
1,170 | $147,809 |
All Filings in MRK
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $469,782 | 3,656 | Shares | Sole | 2026-07-08 | |
| 2026-03-31 | $296,133 | 2,462 | Shares | Sole | 2026-04-14 | |
| 2025-12-31 | $443,013 | 4,209 | Shares | Sole | 2026-01-20 | |
| 2025-09-30 | $68,227 | 813 | Shares | Sole | 2025-10-07 | |
| 2025-06-30 | $1,272,893 | 16,081 | Shares | Sole | 2025-07-07 | |
| 2025-03-31 | $1,161,422 | 12,940 | Shares | Sole | 2025-04-10 | |
| 2024-12-31 | $1,073,726 | 10,794 | Shares | Sole | 2025-01-14 | |
| 2024-09-30 | $1,183,361 | 10,421 | Shares | Sole | 2024-10-11 | |
| 2024-06-30 | $1,219,887 | 9,854 | Shares | Sole | 2024-07-05 | |
| No filing history on record for this holder in this stock. | ||||||